nach oben

Erschienen in:

05.09.2023 | Chest

Value of [¹⁸F]AlF-NOTA-FAPI-04 PET/CT for differential diagnosis of malignant and various inflammatory lung lesions: comparison with [¹⁸F]FDG PET/CT

verfasst von: Kailin Qiao, Xueting Qin, Shuai Fu, Jiazhong Ren, Jing Jia, Xinying Hu, Yuanyuan Tao, Shuanghu Yuan, Yuchun Wei

Erschienen in: European Radiology | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Abstract

Objective

Uptake of the imaging tracers [¹⁸F]AlF-NOTA-FAPI-04 and [¹⁸F]FDG varies in some inflammatory lesions, which may result in false-positive findings for malignancy on PET/CT. Our aim was to compare the [¹⁸F]AlF-NOTA-FAPI-04 and [¹⁸F]FDG PET/CT imaging features of malignant and various inflammatory lung lesions and to analyze their value for differential diagnosis.

Methods

We retrospectively analyzed [¹⁸F]AlF-NOTA-FAPI-04 PET/CT scans from 67 cancer patients taken between December 2020 and January 2022, as well as the scans of 32 patients who also underwent [¹⁸F]FDG PET/CT imaging. The maximum and mean standardized uptake values (SUVmax and SUVmean, respectively) and lesion-to-background ratio (LBR) were calculated. The predictive capabilities of semiquantitative PET/CT parameters were analyzed by receiver operating characteristic curve analysis.

Results

A total of 70 inflammatory and 37 malignant lung lesions were evaluated by [¹⁸F]AlF‑NOTA‑FAPI‑04 PET/CT, and 33 inflammatory and 26 malignant lung lesions also were evaluated by [¹⁸F]FDG PET/CT. Inflammatory lesions exhibited lower [¹⁸F]AlF-NOTA-FAPI-04 and [¹⁸F]FDG uptake compared to malignant lesions, with statistically significant differences in SUVmax, SUVmean, and LBR (all p < 0.001). [¹⁸F]AlF-NOTA-FAPI-04 uptake also varied among different types of inflammatory lesions (SUVmax, p = 0.005; SUVmean, p = 0.008; LBR, p < 0.001), with the highest uptake observed in bronchiectasis with infection, followed by postobstructive pneumonia, and the lowest in pneumonia. [¹⁸F]FDG uptake was higher in postobstructive pneumonia than in pneumonia (SUVmax, p = 0.009; SUVmean, p = 0.016; LBR, p = 0.004).

Conclusion

[¹⁸F]AlF-NOTA-FAPI-04/[¹⁸F]FDG PET/CT showed significantly lower uptake in inflammatory lesions than malignancies as well as variation in different types of inflammatory lesions, and thus, may be valuable for distinguishing malignant and various inflammatory findings.

Clinical relevance statement

Our study confirmed that the uptake of [¹⁸F]AlF-NOTA-FAPI-04/[¹⁸F]FDG PET/CT in inflammatory and malignant lung lesions is different, which is beneficial to distinguish inflammatory and malignant lung lesions in clinic.

Key Points

• Malignant and different inflammatory lung lesions showed varying degrees of uptake of [¹⁸F]AlF-NOTA-FAPI-04 and [¹⁸F]FDG.

• Inflammatory lung lesions showed significantly less uptake than malignancies, and uptake varied among different types of inflammatory lesions.

• Both types of PET/CT could differentiate malignant and various inflammatory lung findings.

Davis SL, Nuermberger EL, Um PK et al (2009) Noninvasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob Agents Chemother 53:4879–4884CrossRefPubMedPubMedCentral

Goo JM, Im JG, Do KH et al (2000) Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. Radiology 216:117–121CrossRefPubMed

Demura Y, Tsuchida T, Ishizaki T et al (2003) 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med 44:540–548PubMed

Alavi A, Gupta N, Alberini JL et al (2002) Positron emission tomography imaging in nonmalignant thoracic disorders. Semin Nucl Med 32:293–321CrossRefPubMed

de Sostoa J, Fajardo CA, Moreno R, Ramos MD, Farrera-Sal M, Alemany R (2019) Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager. J Immunother Cancer 7:19CrossRefPubMedPubMedCentral

Giesel FL, Kratochwil C, Lindner T et al (2019) (68)Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med 60:386–392CrossRefPubMedPubMedCentral

Puré E, Blomberg R (2018) Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics. Oncogene 37:4343–4357CrossRefPubMedPubMedCentral

Altmann A, Haberkorn U, Siveke J (2021) The latest developments in imaging of fibroblast activation protein. J Nucl Med 62:160–167CrossRefPubMed

Loktev A, Lindner T, Mier W et al (2018) A tumor-imaging method targeting cancer-associated fibroblasts. J Nucl Med 59:1423–1429CrossRefPubMedPubMedCentral

10.

Kratochwil C, Flechsig P, Lindner T et al (2019) (68)Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med 60:801–805CrossRefPubMedPubMedCentral

11.

Chen H, Pang Y, Wu J et al (2020) Comparison of [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging 47:1820–1832CrossRefPubMed

12.

Egger C, Cannet C, Gerard C et al (2017) Effects of the fibroblast activation protein inhibitor, PT100, in a murine model of pulmonary fibrosis. Eur J Pharmacol 809:64–72CrossRefPubMed

13.

Li M, Younis MH, Zhang Y, Cai W, Lan X (2022) Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond. Eur J Nucl Med Mol Imaging 49:2844–2868CrossRefPubMedPubMedCentral

14.

Milner JM, Kevorkian L, Young DA et al (2006) Fibroblast activation protein alpha is expressed by chondrocytes following a pro-inflammatory stimulus and is elevated in osteoarthritis. Arthritis Res Ther 8:R23CrossRefPubMedPubMedCentral

15.

Bauer S, Jendro MC, Wadle A et al (2006) Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes. Arthritis Res Ther 8:R171CrossRefPubMedPubMedCentral

16.

Tillmanns J, Hoffmann D, Habbaba Y et al (2015) Fibroblast activation protein alpha expression identifies activated fibroblasts after myocardial infarction. J Mol Cell Cardiol 87:194–203CrossRefPubMed

17.

Heckmann MB, Reinhardt F, Finke D et al (2020) Relationship between cardiac fibroblast activation protein activity by positron emission tomography and cardiovascular disease. Circ Cardiovasc Imaging 13:e010628CrossRefPubMedPubMedCentral

18.

Nagaraju CK, Dries E, Popovic N et al (2017) Global fibroblast activation throughout the left ventricle but localized fibrosis after myocardial infarction. Sci Rep 7:10801CrossRefPubMedPubMedCentralADS

19.

Brokopp CE, Schoenauer R, Richards P et al (2011) Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata. Eur Heart J 32:2713–2722CrossRefPubMedPubMedCentral

20.

Zhao L, Chen S, Lin L et al (2020) [(68)Ga]Ga-DOTA-FAPI-04 improves tumor staging and monitors early response to chemoradiotherapy in a patient with esophageal cancer. Eur J Nucl Med Mol Imaging 47:3188–3189CrossRefPubMed

21.

Luo Y, Pan Q, Zhang W (2019) IgG4-related disease revealed by (68)Ga-FAPI and (18)F-FDG PET/CT. Eur J Nucl Med Mol Imaging 46:2625–2626CrossRefPubMed

22.

Chen H, Zhao L, Ruan D et al (2021) Usefulness of [(68)Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [(18)F]FDG PET/CT findings. Eur J Nucl Med Mol Imaging 48:73–86CrossRefPubMed

23.

Jain S, Self WH, Wunderink RG et al (2015) Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med 373:415–427CrossRefPubMedPubMedCentral

24.

Abers MS, Sandvall BP, Sampath R et al (2016) Postobstructive pneumonia: an underdescribed syndrome. Clin Infect Dis 62:957–961CrossRefPubMed

25.

Burke M, Fraser R (1988) Obstructive pneumonitis: a pathologic and pathogenetic reappraisal. Radiology 166:699–704CrossRefPubMed

26.

Rolston KV (2016) Postobstructive pneumonia in cancer patients. Clin Infect Dis 63:707–708CrossRefPubMed

27.

Valvani A, Martin A, Devarajan A, Chandy D (2019) Postobstructive pneumonia in lung cancer. Ann Transl Med 7:357CrossRefPubMedPubMedCentral

28.

Liu H, Yang X, Liu L, Lei L, Wang L, Chen Y (2021) Clinical significance of diffusely increased uptake of (68)Ga-FAPI in thyroid gland. Front Med (Lausanne) 8:782231CrossRefPubMed

29.

Conen P, Pennetta F, Dendl K et al (2022) [(68) Ga]Ga-FAPI uptake correlates with the state of chronic kidney disease. Eur J Nucl Med Mol Imaging 49:3365–3372CrossRefPubMedPubMedCentral

30.

Glatting FM, Hoppner J, Liew DP et al (2022) Repetitive early (68)Ga-FAPI PET acquisition comparing (68)Ga-FAPI-02, (68)Ga-FAPI-46, and (68)Ga-FAPI-74: methodologic and diagnostic implications for malignant, inflammatory/reactive, and degenerative lesions. J Nucl Med 63:1844–1851CrossRefPubMedPubMedCentral

31.

Dilsizian V, Budde RPJ, Chen W, Mankad SV, Lindner JR, Nieman K (2022) Best practices for imaging cardiac device-related infections and endocarditis: a JACC: Cardiovascular Imaging expert panel statement. JACC Cardiovasc Imaging 15:891–911CrossRefPubMed

32.

Rogers S, Macheda ML, Docherty SE et al (2002) Identification of a novel glucose transporter-like protein-GLUT-12. Am J Physiol Endocrinol Metab 282:E733-738CrossRefPubMed

33.

Shin L, Katz DS, Yung E (2004) Hypermetabolism on F-18 FDG PET of multiple pulmonary nodules resulting from bronchiolitis obliterans organizing pneumonia. Clin Nucl Med 29:654–656CrossRefPubMed

34.

Rohrich M, Leitz D, Glatting FM et al (2022) Fibroblast activation protein-specific PET/CT imaging in fibrotic interstitial lung diseases and lung cancer: a translational exploratory study. J Nucl Med 63:127–133CrossRefPubMedPubMedCentral

35.

Choi EK, Park HL, Yoo IR, Kim SJ, Kim YK (2020) The clinical value of F-18 FDG PET/CT in differentiating malignant from benign lesions in pneumoconiosis patients. Eur Radiol 30:442–451CrossRefPubMed

36.

Ohno Y, Kishida Y, Seki S et al (2018) Amide proton transfer-weighted imaging to differentiate malignant from benign pulmonary lesions: comparison with diffusion-weighted imaging and FDG-PET/CT. J Magn Reson Imaging 47:1013–1021CrossRefPubMed

37.

Giesel FL, Kratochwil C, Schlittenhardt J et al (2021) Head-to-head intra-individual comparison of biodistribution and tumor uptake of (68)Ga-FAPI and (18)F-FDG PET/CT in cancer patients. Eur J Nucl Med Mol Imaging 48:4377–4385CrossRefPubMedPubMedCentral

38.

Parghane RV, Basu S (2017) Dual–time point 18 F-FDG-PET and PET/CT for differentiating benign from malignant musculoskeletal lesions: opportunities and limitations. Semin Nucl Med 47:373–391CrossRefPubMed

39.

Nakajo M, Jinguji M, Aoki M, Tani A, Sato M, Yoshiura T (2020) The clinical value of texture analysis of dual-time-point (18)F-FDG-PET/CT imaging to differentiate between (18)F-FDG-avid benign and malignant pulmonary lesions. Eur Radiol 30:1759–1769CrossRefPubMed

Titel: Value of [18F]AlF-NOTA-FAPI-04 PET/CT for differential diagnosis of malignant and various inflammatory lung lesions: comparison with [18F]FDG PET/CT
verfasst von: Kailin Qiao
Xueting Qin
Shuai Fu
Jiazhong Ren
Jing Jia
Xinying Hu
Yuanyuan Tao
Shuanghu Yuan
Yuchun Wei
Publikationsdatum: 05.09.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: European Radiology / Ausgabe 3/2024
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-023-10208-y

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Value of [¹⁸F]AlF-NOTA-FAPI-04 PET/CT for differential diagnosis of malignant and various inflammatory lung lesions: comparison with [¹⁸F]FDG PET/CT